Developing novel inhibitors of the GUT microbiome to modulate drug metabolism
Ended Project Grant Awarded Last action
- Award ID
- R44TR002691
- Recipient
-
Symberix, Inc. UEI HN72U2V5AKN7
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,213,854
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date
- Originally
- Funding
-
- $2,426,165.00 Federal
- $787,689.00 Non-federal
- Place of performance
- Durham, NC 27703, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $787,689 | $0 | |
| Amendment | $787,689 | $787,689 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $625,834 | $0 | |
| Original award | $224,953 | $0 |
Quick answers
Who received award R44TR002691?
R44TR002691 was awarded to Symberix, Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on May 1, 2019.
How much is award R44TR002691 worth?
$3,213,854 has been obligated on R44TR002691: $2,426,165 in federal funding and $787,689 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award